NmVac4-A/C/Y/W-135 is the commercial name of the polysaccharide vaccineagainst the bacterium (specifically serogroups A, C, Y, and W-135) that causes meningococcal meningitis. The product, by JN-International Medical Corporation, is designed and formulated to be used in developing countries for protecting populations during meningitis disease epidemics.
Meningococcal meningitis is a bacterial infection caused by the bacterium Neisseria meningitidis, also known as meningococcus. The vaccine is made from bacterial capsular polysaccharides through fermentation of each individual serogroup of Neisseria meningitidis in bioreactors. After fermentation, the polysaccharides are purified, formulated, and lyophilized using preservatives and stabilizers to make a vaccine product. The vaccine cannot protect from other serogroups of N. meningitidisand cannot eliminate the chance of infection by these serogroups.
Military recruits[edit]
Because the risk of meningococcal disease is increased among military recruits, all military recruits routinely receive primary immunization against the disease.[8]
https://en.wikipedia.org/wiki/NmVac4-A/C/Y/W-135
No comments:
Post a Comment